HRSA Determines Six Manufacturers’ Contract Pharmacy Policies Violate 340B Statute
Yesterday, HRSA Acting Administrator Diana Espinosa sent letters to Eli Lilly, AstraZeneca, Novartis, Novo Nordisk, Sanofi, and United Therapeutics making
340B providers filed an amicus brief in opposition to AstraZeneca’s motion to invalidate Advisory Opinion.
On May 4, 2021, 340B safety-net providers and their trade associations filed a brief in the case brought by AstraZeneca Pharmaceuticals LP (AstraZeneca)
Arkansas Passes Comprehensive 340B Anti-Discriminatory Reimbursement Bill, Protects Covered Entities Rights to Use Contract Pharmacies
Last week, Arkansas passed legislation (HB 1881) intended to address 340B discriminatory pricing practices by third party payers and pharmacy benefit
Indiana General Assembly passes landmark 340B anti-discrimination bill (HB 1405)
On April 22, 2021, the Indiana General Assembly passed a bill (HB 1405) that protects Indiana 340B safety-net providers from discriminatory and predatory
United Therapeutics Announces Details on Phase Two of its Restrict Contract Pharmacy Policy
By letter dated April 12, drug manufacturer United Therapeutics (UT) announced additional details regarding the second phase of its restrictive contract
Gilead Delays Harmful Changes to Patient Assistance Program Until January 1, 2022
Last week, Gilead issued a statement that it is delaying a change to its Advancing Access® Patient Assistance/Medication Assistance Program (PAP/MAP) until
New York Delays Controversial Pharmacy Carve Out for Two Years
On April 6th, 2021, the New York legislature announced that it was delaying a controversial policy that would require the New York Medicaid program to
New Research Shows 340B Hospitals Provide More Medication Access Services Than Non-340B Hospitals
Below is a press release issued by CV340B highlighting new research showing that 340B hospitals provide more medication access services than non-340B
Op-ed by Prominent Community Leaders Highlights Severe Damage of New York’s Proposed Medicaid Carve-out
On March 23, an op-ed written by three prominent community leaders, Ms. Hazel Dukes, Rev Kirsten John Foy, and Rev Dr. Johnnie Green, was published in
Webinar: The Impact of Women in the 340B Drug Pricing Program
In this webinar sponsored by CV-340B, our panel of four exceptional leaders at the forefront of 340B will discuss the impact of women in 340B. The speakers